WATCH: Marija Balic, MD, PhD, discusses the potential role of tumor-informed ctDNA testing in early triple-negative breast cancer. @upmchillmancc.bsky.social @theaacr.bsky.social #bcsm #oncology

See our coverage of the #AACR26 for more insights!

www.onclive.com/conference/a...

Cilta-Cel Generates 100% ORR, MRD-Negativity Rate in High-Risk Smoldering Myeloma | OncLive Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial.

Cilta-cel demonstrated feasibility in the treatment of patients with high-risk smoldering multiple myeloma in the phase 2 CAR-PRISM trial. @danafarber.bsky.social @theaacr.bsky.social #AACR26 #mmsm #hematology

www.onclive.com/view/cilta-c...

OncoExTra and OncoDetect Identify Actionable Biomarkers and ctDNA Status in Breast and Colorectal Cancers | OncLive Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctDNA status.

Molecular testing identified actionable alterations in high proportions of patients with breast and colorectal cancers, regardless of ctDNA status. @theaacr.bsky.social #AACR26 #bcsm #crcsm #oncology

www.onclive.com/view/oncoext...

Selection and Timing Are Critical Components for TIL Therapy in Advanced Melanoma | OncLive Douglas B. Johnson, MD, MSCI, discusses the use of TIL therapy in melanoma, including patient selection, sequencing, timing, and emerging applications beyond skin cancer.

Douglas B. Johnson, MD, MSCI, of @vumedicine.bsky.social discusses the use of TIL therapy in melanoma, including patient selection, sequencing, timing, and emerging applications beyond skin cancer. #oncology #melanoma
www.onclive.com/view/selecti...

Zoldonrasib Displays Early Safety, Efficacy in Pretreated KRAS G12D–Mutated NSCLC | OncLive Zoldonrasib produced responses and no grade 4 or 5 TRAEs in previously treated KRAS G12D–mutated NSCLC.

🧬 Early-phase data show zoldonrasib delivers promising efficacy and a favorable safety profile in heavily pretreated KRAS G12D–mutated NSCLC—a space with no approved targeted options. 📊
Read more ➡️ www.onclive.com/view/zoldonr...
#LungCancer #NSCLC #KRAS #TargetedTherapy #Oncology #AACR26

Dr Sun on the Importance of Biomarker Testing in Head and Neck Cancers | OncLive Fangdi Sun, MD, discusses how biomarker testing can help navigate the complexity of treatment decision-making across the spectrum of head and neck cancers.

WATCH: Fangdi Sun, MD, discusses how biomarker testing can help navigate the complexity of treatment decision-making across the spectrum of head and neck cancers. @stanfordmedicine.bsky.social #hncsm #oncology

www.onclive.com/view/dr-sun-...

After approving perioperative enfortumab vedotin plus pembrolizumab in November 2025 for cisplatin-ineligible MIBC, the FDA has granted priority review for the combination in the cisplatin-eligible population. #blcsm #oncology

Read more: www.onclive.com/view/periope...

Retrospective Data Highlight Challenges, Potential Therapeutic Strategies With Allo-HSCT in Myelofibrosis and BP-MPNs | OncLive Relapse following allo-HSCT remains frequent and represents an ongoing therapeutic challenge for patients with myelofibrosis or BP-MPNs.

Relapse following allo-HSCT remains frequent and represents an ongoing therapeutic challenge for patients with myelofibrosis or BP-MPNs. @theebmt.bsky.social #EBMT26 #hematology #oncology

www.onclive.com/view/retrosp...

With the @theaacr.bsky.social Annual Meeting officially underway, experts preview some of the most anticipated abstracts, including key data in lung, breast, and ovarian cancers #AACR26 #oncology

Sign up and read our exclusive preview and expert insights: www.onclive.com/view/oncolog...

WATCH: Alicia Morgans, MD, MPH, of
@danafarber.bsky.social
discusses the safety profile and AE management of mevrometostat in mCRPC. #oncology #pcsm #CRPC
www.onclive.com/view/dr-morg...

Dr Kato on the MONSTAR-Screen-3 Study in Resectable RCC | OncLive Taigo Kato, MD, PhD, discusses the background of the MONSTAR-SCREEN-3 in resectable RCC and the key findings from the study.

WATCH: Taigo Kato, MD, PhD, discusses the background of the MONSTAR-SCREEN-3 in resectable RCC and the key findings from the study. #oncology #GU26 #RCC #kcsm
www.onclive.com/view/dr-kato...

Dr Schweizer on the Background of the MEVPRO-1 and MEVPRO-2 Trials in mCRPC | OncLive Michael Schweizer, MD, discusses the mechanism of action of mevrometostat and early-phase data with the agent in mCRPC.

WATCH: Michael Schweizer, MD, of @fredhutch.org discusses the mechanism of action of mevrometostat and early-phase data with the agent in mCRPC. #oncology #pcsm #prostatecancer
www.onclive.com/view/dr-schw...

Dr Flanagan on Crucial Radiation Therapy Conversations for Breast Cancer | OncLive Meghan R. Flanagan, MD, MPH, discusses the evolution of radiation therapy protocols following surgery for patients with breast cancer.

Meghan R. Flanagan, MD, MPH, discusses the evolution of radiation therapy protocols following surgery for patients with breast cancer. @fredhutch.org @uwmedicine.bsky.social #MBCC26 #bcsm #oncology

www.onclive.com/view/dr-flan...

Sara Nunnery, MD, MSCI, of Tennessee Oncology stopped by to record the next episode of Breast Cancer Briefing to unpack the latest news in breast cancer research! Stay tuned to onclive.com for all of the highlights from our interview #oncology #LightsCameraMJH #bcsm

Thank you to our first interviewee of the day @mpishvaian.bsky.social of Johns Hopkins who discussed biomarkers in GI cancers. Check back on onclive.com for all of the highlights from our conversation #oncology #LightsCameraMJH #GIcancer

We are all set and excited for our studio day recordings! Stay tuned to onclive.com for highlights from our sessions featuring conversations with top oncologists from across the country.
#oncology #LightsCameraMJH

WATCH: Ranee Mehra, MD, highlights the importance of PD-L1 testing for head and neck cancer. #hncsm #oncology

Check out our head and neck cancer page for more expert insights!

www.onclive.com/clinical/hea...

Dr Flanagan on Coordinating Breast Cancer Treatment De-Escalation Strategies | OncLive Meghan R. Flanagan, MD, MPH, discusses the multidisciplinary complexities that arise when trying to coordinate de-escalated breast cancer care.

WATCH: Meghan R. Flanagan, MD, MPH, discusses the multidisciplinary complexities that arise when trying to coordinate de-escalated breast cancer care. @fredhutch.org @uwmedicine.bsky.social #MBCC26 #bcsm #oncology

www.onclive.com/view/dr-flan...

WATCH: Rena D. Callahan, MD, spotlights the future of triple-negative breast cancer management. @uclahealth.org #bcsm #oncology

Check out our breast cancer page for more expert insights!

www.onclive.com/clinical/bre...

Dr Flanagan on Debates About Genomic Assays for DCIS Treatment Decision-Making | OncLive Meghan R. Flanagan, MD, MPH, notes takeaways from a multidisciplinary tumor board discussion on how genomic assays can guide treatment decisions for DCIS.

Meghan R. Flanagan, MD, MPH, notes takeaways from a multidisciplinary tumor board discussion on how genomic assays can guide treatment decisions for DCIS. @fredhutch.org @uwmedicine.bsky.social #MBCC26 #bcsm #oncology

www.onclive.com/view/dr-flan...

Unpacking the Advantages and Limitations of Leading Frontline Regimens in EGFR-Mutated NSCLC | OncLive Susan Scott, MD, Julia Rotow, MD, and Enriqueta Felip, MD, PhD, debate the optimal choice of frontline regimen for EGFR-mutated NSCLC.

🧬 From osimertinib monotherapy to osimertinib + chemo and emerging regimens like amivantamab + lazertinib, clinicians now face key trade-offs in efficacy, toxicity, and sequencing.
Read more ➡️ www.onclive.com/view/unpacki...
#LungCancer #NSCLC #PrecisionOncology #TargetedTherapy #Oncology

Aaron Gerds, MD, MS, of Cleveland Clinic, breaks down the rationale for targeting CALR mutations and the drive for precision medicine approaches in MPNs #oncology

Watch more from the interview here: www.onclive.com/view/dr-gerd...

FDA Grants Fast Track Designation to OPN-6602 for R/R Myeloma | OncLive OPN-6602 received FDA fast track designation for relapsed/refractory multiple myeloma after at least 4 prior lines of therapy.

🚀 The FDA has granted Fast Track designation to OPN-6602, an oral EP300/CBP inhibitor targeting novel transcriptional dependencies in heavily pretreated R/R multiple myeloma. 🧬
Read more ➡️ www.onclive.com/view/fda-gra...
#MultipleMyeloma #HemeOnc #ClinicalTrials #Oncology

Christian Capitini Named Director of the UW Carbone Cancer Center | OncLive Christian Capitini has been named the next director of the University of Wisconsin Carbone Cancer Center.

Christian Capitini has been named the next director of the University of Wisconsin Carbone Cancer Center. #oncology
www.onclive.com/view/christi...

Clairity Breast Is Added to NCCN Guidelines for Breast Cancer Screening and Diagnosis | OncLive The NCCN updated its 2026 Guidelines for breast cancer screening and diagnosis to include an AI-based risk assessment tool to predict breast cancer risk.

The NCCN has updated its 2026 Clinical Practice Guidelines for breast cancer screening and diagnosis to include Clairity Breast, an AI-based tool that analyzes mammograms and assesses future risk for breast cancer development #bcsm #oncology

Read more: www.onclive.com/view/clairit...

WATCH: Bradley J. Monk, MD, FACS, FACOG, of Florida Cancer Specialists & Research Institute discusses the final analysis of the phase 3 KEYNOTE-B96 trial in platinum-resistant recurrent ovarian cancer.
#Oncology #SGO2026 #gynsm
www.onclive.com/view/dr-monk...

Mirvetuximab Soravtansine Plus Carboplatin Is Active in Platinum-Sensitive Ovarian Cancer | OncLive Mirvetuximab soravtansine plus carboplatin showed antitumor activity and a manageable safety profile in patients with recurrent platinum-sensitive ovarian cancer.

🧬 Mirvetuximab soravtansine + carboplatin demonstrated encouraging antitumor activity in platinum-sensitive ovarian cancer, supporting expansion of this ADC beyond the platinum-resistant setting. 📊
Read more ➡️ www.onclive.com/view/mirvetu... #gyncsm #oncology #SGOAM26

Tisotumab Vedotin With Carboplatin/Pembrolizumab ± Bevacizumab Shows Activity in Cervical Cancer | OncLive Tisotumab vedotin plus carboplatin & pembrolizumab ± bevacizumab achieved 65.8% ORR and 28-month median OS in first-line recurrent/metastatic cervical cancer.

💊 Promising data from #SGOAM26: Tisotumab vedotin + carboplatin + pembrolizumab ± bevacizumab delivered a 65.8% response rate and a median OS of 28 months in first-line recurrent/metastatic cervical cancer.

Learn more: 🔗 www.onclive.com/view/tisotum... #gyncsm #medtwitter #oncology

🎙️Watch or listen to the latest episode of Breast Cancer Briefing with Sara Nunnery, MD, & @neil-iyengarmd.bsky.social! @winshipcancer.emory.edu #bcsm #oncology

www.onclive.com/view/lifesty...

Dr Olawaiye on the Final OS Data From the Phase 3 ROSELLA Trial in Platinum-Resistant Ovarian Cancer | OncLive Alexander Olawaiye, MD, discusses the final overall survival data from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer.

WATCH: Alexander Olawaiye, MD, of @upmchillmancc.bsky.social discusses the final overall survival data from the phase 3 ROSELLA trial in platinum-resistant ovarian cancer. #ovca #gynsm #SGOAM26
www.onclive.com/view/dr-olaw...